Claudio Dansky Ullmann

Claudio Dansky Ullmann, M.D., brings more than 30 years of experience in early and late-stage oncology therapeutics drug development, both solid tumors and hematologic malignancies, in pharmaceutical, biotechnology, government, and academic settings. As a member of executive leadership teams, he oversaw clinical development, operations, and regulatory activities, helped shape corporate strategy, directly involved in business development activities as well as investor and analyst interactions. Dr. Dansky Ullmann was most recently the Chief Medical Officer at MaxCyte, responsible for the development of CARMA™ cell therapy program. Previously, he was the Senior Vice President, and Head of Clinical Development at Infinity Pharmaceuticals, where he led the development of Copiktra until FDA approval, and of eganelisib through first in human studies. Earlier, he was Senior Medical Director, Global Clinical Lead in the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Before, Dr. Dansky Ullmann worked at the Cancer Therapy Evaluation Program, National Cancer Institute, as a Senior Investigator involved in the strategic development of novel agents and therapeutic modalities, including numerous phase 1-3 clinical trials. He was also involved in the development of immunotherapies at Biomira, Inc. and held research fellowship positions in tumor immunotherapy and drug resistance at the NCI. Dr. Dansky Ullmann is a native of Argentina and earned his M.D. at the School of Medicine, Universidad de Buenos Aires. He completed his medical oncology training at Guemes Private Hospital, Buenos Aires.